Opinion|Videos|February 27, 2025
Fostering Open Discussions With Women About Menopausal Symptoms
Panelists explain how health care professionals evaluate menopause symptoms using validated questionnaires, symptom tracking, clinical interviews, hormonal tests, and patient-reported outcome measures to comprehensively assess severity and quality-of-life impact.
Advertisement
Video content above is prompted by the following:
- What tools or strategies do you use to evaluate the severity of menopause symptoms and the effect of symptoms on quality of life?
- How can health care providers, who are not experts on women’s health, provide information and resources related to women’s health?
Advertisement
Related to this article
Investigational antiamyloid monoclonal antibodies may offer a novel pathway to disease reversal.
Increasingly, pharmacists are leading the obesity management team.
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
A panel of cardiology pharmacists discussed the diagnostic red flags, evolving treatment landscape, and expanding pharmacist role central to identifying and managing ATTR-CM.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
EMBER-3 data show switching to the combination at progression nearly doubled PFS versus imlunestrant alone in ESR1-mutated advanced breast cancer.
Tim Cernohous of Cencora explains why patient trust no longer guarantees satisfaction—and how automation and better communication can close the gap with mail order.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Eight Names, One Drug: Why Adalimumab Biosimilars Are Creating Real Confusion at the Counter
2
New Data Reshapes Nonstatin Lipid Therapy Choices
3
Etentamig Reduces Risk of Progression or Death by 60% in Relapsed/Refractory Multiple Myeloma
4
Bridging the Gap: Pharmacist Experiences Obtaining DEA Licenses
5